Immunotherapy can significantly extend survival time in patients with advanced bowel cancer

June 2, 2020 /PRNewswire/--- A large international clinical trial by UCL and University College Hospitals NHS Foundation Trust (UCLH) found that pembrolizumab (which can more than double the progression of "progression survival" in patients with certain subtypes of advanced bowel cancer is more than doubled) compared to chemotherapy"progression-free survival" refers to the length of time the patient survives treatment for the disease (e.gcancer) and after treatment, but the patient's condition does not worsen in this caseIn clinical trials, measuring progression-free survival is one way to observe the effectiveness of new therapiesas part of a mid-term analysis of clinical trial data conducted at the annual meeting of the American Society of Clinical Oncology (ASCO), the researchers found that patients treated with pembrolizumab (also known as Keytruda) had a non-progressive survival of 16.5 months (on average), compared with 8.2 months for patients receiving chemotherapyin addition, 11 percent of patients treated with pembrolizumab also experienced "complete remission" after disappearing from the scanin addition, almost half of patients treated with pembrolizumab (48.3%) did not worsen after two years, compared with only one in five (18.6%) who received chemotherapy, which means long-lasting beneficial effectsDr Kai-Keen Shiu, M.D., consultant oncologist at UCL Cancer Research, a lead researcher in the UK whothe trial, said: "This is the first randomized controlled study to show that first-line immunotherapy has a significant advantage over chemotherapy in reducing metastatic bowel cancer with these specific DNA mutations and has increased the time required for cancer developmentAlthough only about 5 percent of people with advanced bowel cancer have these genetic mutations, they usually have poor prognosis and poor response to chemotherapy and other targeted drugsThe results of this trial have indeed changed the game and will almost certainly lead to a paradigm shift in our current clinical practice"Bio Valley Bioon.comSource:'s Immunotherapy Syds Progression-free survival time of patients with the cancer